

10 March 2025

## Section 708A Cleansing Notice

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), advises that it has today issued 72,847,867 fully paid ordinary shares ("Shares").

### Section 708A Cleansing Notice

In accordance with section 708A(5)(e) of the Act, the Company gives notice that:

1. the Shares were issued without disclosure to investors under Part 6D.2 of the Act;
2. as at the date of this notice, the Company has complied with the provisions of Chapter 2M of the Act, as they apply to the Company and sections 674 and 674A of the Corporations Act 2001 (Cth); and
3. as at the date of this notice there is no information that is 'excluded' information within the meanings of section 708A(7) and 708A(8) of the Act, being information:
  - a) that has been excluded from a continuous disclosure notice in accordance with the ASX Listing Rules;
  - b) that investors and their professional advisers would reasonably require for the purposes of making and informed assessment of:
    - i. the assets and liabilities, financial position and performance, profits and losses and prospects of the Company; or
    - ii. the rights and liabilities attaching to the Securities.

-ENDS-

For further information, investors and media please contact:

**Mr Marjan Mikel**  
CEO & Managing Director  
Respiri Limited  
P: +61 408 462 873  
E: [marjan@respiri.co](mailto:marjan@respiri.co)

**Mr Nicholas Smedley**  
Executive Chairman  
Respiri Limited  
P: +61 447 074 160  
E: [nicholas@respiri.co](mailto:nicholas@respiri.co)

*This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.*

---

#### About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We're revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at [www.respiri.co/au](http://www.respiri.co/au)

**About the wheezo® Medical Device**

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.

wheezo® is a registered trademark of Respiri Limited